Minerva Gastroenterologica e Dietologica (New title: Minerva Gastroenterology) EDIZIONI MINERVA MEDICA

The Enigma of Vitamin D supplementation in Aging with Obesity

Journal: Minerva Gastroenterologica e Dietologica (New title: Minerva Gastroenterology) Paper code: Minerva Gastroenterol-2955 Submission date: May 28, 2021 Article type: Review Article

Files:

- Reply letter to comments on the manuscript Version: 5 Description: File format: application/vnd.openxmlformats-officedocument.wordprocessingml.document
- 2. Manuscript Version: 6

Description: clear revised manuscript with table File format: application/vnd.openxmlformats-officedocument.wordprocessingml.document

3. Supplementary Digital Material 1
 Version: 2
 Description: revised table 1
 File format: application/vnd.openxmlformats-officedocument.wordprocessingml.document

Page 1 of 24

Editorial revision form
<u>-1</u> 2
QUESTIONS
-pag 1/8 line 44 to add to reference number 4 the paper by Curic et al "MINERVA MEDICA "
Vélume: 109 Issue: 2 Pages: 79-87
7 8
9
-mage 4/8 line 16 to add to reference 21 the following Riobaldone et al. MINERVA GASTROENTEROLOGICA L1 DIETOLOGICA 2020;â€□: 66 2 Pages: â€□ 106-112 12
Ripaldone, D.G., Astegiano, M., Actis, G.C. and Pellicano, R., 2020. Management of inflammatory bowel disease during
GGVID-19 pandemic.
17 A&NSWERS. I included / replaced the following references.
20 21
22
23 24
25 Symone PERNA ¹
27
28
Bepartment of Biology, College of Science, University of Bahrain, P.O. Box 32038, Sakhir, Bahrain.
31
32 33
34 Gerresponding author: Simone Perna, Section, Department of Biology, College of Science, University of
Bahrain, P.O. Box 32038, Sakhir, Bahrain. Mail correspondence simoneperna@hotmail.it
38 39
Abstract
41 IATRODUCTION: The American Geriatrics Society recommends a minimum daily supplement of 1,000 IU and
underlines that a dosage lower than 600 IU do not prevent falls in elderly people.
BYIDENCE ACQUISITION: Review author searched on PubMed, Medline, Embase, Scopus database (last
⁴⁶ sparch May 30, 2021), with the MeSH terms and keywords of vitamin D, (25(OH)D), elderly and obesity. This
$\frac{48}{49}$ review article aims to support the rationale on the correct vitamin D supplementation in elderly people with
699esity and overweight.
EXIDENCE SYNTHESIS: 10 studies were found suitable for consideration in writing this comprehensive
53 gyidence-based rapid review. The supplementation of vitamin D included 1500 elderly subjects with Body Mass
$\frac{1}{10}$
is highly recommended in elderly people with obesity because 1) sequestration of vitamin D by the adipose tissue

Page 2 of 24

2) increased catabolism of vita-in D in the adipose tissue 3) decreased synthesis of serum 25 hydroxyvitamin D
 (25(OH)D) in the liver 4) reduced sun-exposure. 5) Dosages equal at 1000 UI or lower do not show and important
 effect on vitamin d deficiency and related comorbidities in elderly people with obesity.

 C_{Q}^{3} NCLUSIONS: Gender, baseline levels of serum (25(OH)D) concentration, ethnicity and severity of BMI should be accounted for the correct supplementation of vitamin D in elderly population for the precision medicine $g\overline{d}_{al}$.

INTRODUCTION.

The vitamin D system includes a group of fatty-soluble prohormones and their corresponding metabolites. [1]. There are two main forms of vitamin D in nature: vitamin D2 (ergocalciferol), photochemically synthesized in plants, and vitamin D3 (cholecalciferol), synthesized by the skin in response to exposure to sunlight. The levels of vitamin D derive mainly from the endogenous skin production stimulated by sunlight and by oral intake [2-3]. In elderly people have been demonstrated that there is an inverse association between serum 25 (OH) D concentration and a Body Mass Index (BMI) greater than 25 kg/m2 [4].

 $\frac{10}{4}$ unclear whether this association is due to increased fat deposition, a sedentary lifestyle, low sun exposure, diffect vitamin D deficiency, genetic changes in vitamin D metabolism, or other unknown factors [5],

The presence of a vitamin D deficiency in obese people shows a negative relationship between (25(OH)D) and body fat percentage. This marked unbalanced ration is higher for some ethnicities, and the relationship is more evident in older people rather than young [6]. Furthermore, some studies have shown that the reduction on body ₩ and percentage of fat mass are associated with an increase in circulating levels of (25(OH)D) [7,8]. There are several reasons behind of this situation: 1) the volumetric dilution, in particular, the serum levels of vitamin 22 Bare reduced as well as body mass and therefore the amount stored in fat increases, 2) different lifestyles between 24 ese and underweight people 3) different ability to activate vitamin D between obese and underweight people able to the levels of the enzymes activating vitamin D, 25-hydroxylase CYP2J2 and 1a-hydroxylase CYP27B1, 27 $\frac{1}{9}$ the sequestration of vitamin D into the adipose tissue [9].

The aim of this review is to shed in light and define the dose-efficacy of the vitamin D supplementation in elderly HO CH Patients with overweight and obesity.

33

34 EXIDENCE ACQUISITION

this systematic review was performed according to the following steps suggested by Egger [10]: (i) configuration **B**a working group; (ii) formulation of the revision question on the basis of considerations made in the abstract; (iii) identification of relevant studies. The search involved all the studies published from the 1st of January 2010 the 30th May 2021. English written articles were identified by searching on PubMed, Medline, Embase, Scopus database (last search May 30, 2021), with the MeSH terms and keywords of vitamin D, (25(OH)D), elderly and øbsesity.

 (\mathfrak{SP}) independently reviewed each report. For each of the relevant abstracts, full publications were retrieved for $\frac{48}{2}$ evaluation on the basis of criteria established a priori.

Signal clinical trials investigating the effects of vitamin D supplementations (divided for dose intervention) in egglerly patients were evaluated. The change of vitamin D level (t1 minus t0 basal level) was the primary outcome $\frac{53}{considered}$. Only elderly patients with age over 65 years old were included with overweight and obesity. The elfgible studies were required to report baseline and follow-up values, i.e. the mean change from baseline (Δ change) and/or the mean difference Δ -changes (MD Δ) between intervention groups for Vitamin D outcome.

EVIDENCE SYNTHESIS

Table 1 shows 10 studies with more than 1500 elderly subjects with overweight and obesity. All studies showed a a glinical effect of vitamin D supplementation compared to placebo, but significant effects "between groups" were reported in studies with daily supplementation from 2000 to 4000 UI. Sollid, 2014 et al (11) reported an increase of 45.8 nmol/L in intervention group with vitamin D 20.000 UI/weekly compared with placebo 3.4 nmol/L, respectively, nevertheless a situation of obesity.

Sumilar effects were reported in the study of Tomi-Pekka with a supplementation of $80 \mu g/d$ vitamin D3 daily (12), but not in the study of Macdonald with a lower supplementation (1000 UI daily) (13).

In 2017, Levis at al, showed that daily cholecalciferol 4,000 IU for 9 months increased the (25(OH)D) 15 experimentations, nevertheless the population was with obesity (14).

There was not recorded any improvement in (25(OH)D) on recent clinical trials with low dosages (15-17). Very inferesting data were reported by 3 recent studies (18-20) that reported an high efficacy of vitamin D applementation ((25(OH)D) increased +50% from baseline) in obese patients at dosages of vitamin D (from 22,000 to 300.000 IU).

24

25 **26**NCLUSIONS

 $\frac{25}{29}$ is review shows that in elderly patients with a BMI over 25 kg / m2 (both in overweight and obese) a daily $\frac{29}{29}$ and $\frac{29}{29}$ and $\frac{29}{29}$ and $\frac{29}{29}$ and $\frac{29}{29}$ (OH)D) instead the normal recommended dosage of 1000-800 IU daily.

BBthis category of patients, the areas of effectiveness of vitamin D intake are multiples such as the quality of life, $\frac{34}{100}$ prevention of sarcopenia, the reduction of depression, the reduction in the incidence of fractures, pain $\frac{36}{100}$ luction, the reduction in the incidence of infections and the improvement of physical function (21-23)

C8 nsidering the positive effects of vitamin D in elderly on the following areas, the identified dosage must be $\frac{39}{39}$ stondardized whenever possible, at 2000 IU / day and above when it is possible.

 $\frac{41}{42}$ effects of vitamin D supplementation was found in situations of sarcopenia (at the dose of 800 IU [16]), to $\frac{43}{44}$ prove physical functions at the dose of 400 IU [22]), cytokine suppression at the dose of 750 IU [23]), blood $\frac{44}{44}$ patersure and glucose homeostasis (from 250 to 400 IU [24-26]).

 $\frac{40}{29}$ rthermore the patients with obesity (BMI over 30Kg / m2) have found positive effects (at doses ranging from $\frac{28}{29}$ 00 to 4000 IU daily) in improving physical functions, in association between protein intake and bone mineral $\frac{49}{29}$ density, and increased concentration of serum 25 (OH) D levels, the latter factor is of great scientific interest and $\frac{51}{51}$ effective timportance, as it can determine (through the presence of fat mass) a sequestration of the supplemented $\frac{53}{54}$ amin D. (27)

ff is known that the concentrations of serum (25(OH)D) are less in obese individuals and in particular in elderly. There are several mechanisms described in the literature that shows the involvement of vitamin D in adipose

Page 5 of 24

tissue metabolism and catabolism in elderly. Summarizing this founding, the vitamin D supplementation over 2000 UI is highly recommended in elderly obese because 1) sequestration of vitamin D by the adipose tissue 2) increased catabolism of vitamin D in the adipose tissue 3) decreased synthesis of 25(OH)D in the liver 4) reduced sun-exposure. This study lays the foundation for identifying the effectiveness of proper vitamin D supplementation in elderly patients with obesity. The importance of supplementation must be assessed by taking into consideration various determining factors such as: the basal serum dose, gender, age and the BMI Author Contributions: SP is full responsible for "Conceptualization; methodology; resources; writing-original draft preparation, and review and editing, Funding: "This research received no external funding" c_{8}^{7} of Interest: The authors declare no conflict of interest." HIMER VAL

REFERENCES

1 2 1.	Liu H, Li J, Du L, Yang M, Yang D, Li J, et al. Short-term effects of core stability training on the
3 4	balance and ambulation function of individuals with chronic spinal cord injury: a pilot randomized
5	controlled trial. Minerva Med 2019;110:216-23.
6 7	controlled that. White valued 2019,110.210-23.
8 9 2. 10 11 12	Sirajudeen S, Shah, I, Al Menhali, A. A narrative role of vitamin D and its receptor: with current evidence on the gastric tissues. International journal of molecular sciences 2019 20(15), 3832.
13 14 3.	Giuliani S, Barbieri V, Di Pierro A, M Rossi F, Widmann T, Lucchiari M, Herrmann M, LC-MS/MS
15 16	based 25 (OH) D status in a large Southern European outpatient cohort: gender-and age-specific
17 18 19	differences. European journal of nutrition 2019 58(6), 2511-2520
20 21 <mark>4.</mark>	Curic N, Ilincic B, Milic N, Cabarkapa V, Nikolic S, Medic-Stojanoska M, Pellicano R, Abenavoli L. The
22	relationship between the vitamin serum 25 (OH) D and the B12 concentrations in obese women. Minerva
23 24	
25	medica. 2017: 7;109(2):79-87.
26 27 5.	Charoenngam N, Shirvani A, Holick MF. Vitamin D for skeletal and non-skeletal health: What we should
28 29	know. Journal of clinical orthopaedics and trauma 2019.10(6), 1082-1093.
30	
31 32 6.	Gallagher JC, Peacock M, Yalamanchili V, Smith LM. Effects of vitamin D supplementation in older
22	
34 35 36	African American women. The Journal of Clinical Endocrinology & Metabolism 2013:1;98(3):1137-46.
37 38 7.	Parva NR, Tadepalli S, Singh P, Qian A, Joshi R, Kandala H, Nookala VK, Cheriyath P. Prevalence of
39	vitamin D deficiency and associated risk factors in the US population (2011-2012). Cureus 2018:10(6).
40 41	
42 43 8.	Vilarrasa N, Maravali J, Estepa A, Sanchez R, Masdevall C, Navarro MA, Alía P, Soler J, Gómez JM.
44 45	Low 25-hydroxyvitamin D concentrations in obese women: their clinical significance and relationship
46	with anthropometric and body composition variables. Journal of endocrinological investigation.
47 48	2007:30(8):653-8.
49 50	
50 51 9.	Mazahery H, Von Hurst PR. Factors affecting 25-hydroxyvitamin D concentration in response to vitamin
52 53	D supplementation. Nutrients 2015:7(7):5111-42.
54 55	
JJ	

	10.	Abbas MA. Physiological functions of Vitamin D in adipose tissue. The Journal of steroid biochemistry
1		and molecular biology 2017:165, 369-381.
2		
3 4	11.	Egger, M., Davey-Smith, G. and Altman, D. eds., 2008. Systematic reviews in health care: meta-analysis
5 6		in context. John Wiley & Sons.
7		
8 9	12.	Sollid ST, Hutchinson MY, Fuskevåg OM, Figenschau Y, Joakimsen RM, Schifmer H, Njølstad I,
10 11		Svartberg J, Kamycheva E, Jorde R. No effect of high-dose vitamin D supplementation on glycemic status
12 13		or cardiovascular risk factors in subjects with prediabetes. Diabetes care 2014:1;37(8):2123-31.
14		
15 16	13.	Tuomainen TP, Virtanen JK, Voutilainen S, Nurmi T, Mursu J, de Miello VD, Schwab (), Hakumäki M,
17 18		Pulkki K, Uusitupa M. Glucose metabolism effects of vitamin D in prediabetes: the VitDmet randomized
19 20		placebo-controlled supplementation study. Journal of diabetes research. 2015 27;2015.
21		
22 23	14.	Macdonald HM, Wood AD, Aucott LS, Black AJ, Fraser WD, Mayroeidi A, Reid DM, Secombes KR,
24 25		Simpson WG, Thies F. Hip bone loss is attenuated with 1000 RU but not 400 IU daily vitamin D3: a 1-
26 27		year double-blind RCT in postmenopausal women. Journal of Bone and Mineral Research.
28		2013:28(10):2202-13.
29 30		
31 32	15.	Levis, S., & Gómez-Marín, O. (2017). Vitamin D and physical function in sedentary older men. Journal
33		of the American Geriatrics Society, 65(2), 323-331.
34 35		
36 37	16.	Wijnen H, Salemink D, Roovers L, Paekema D, de Boer H. Vitamin D supplementation in nursing home
38 39		patients: randomized controlled trial of standard daily dose versus individualized loading dose regimen.
40		Drugs & aging. 2015:1:32(5):371-8.
41 42		
43 44		
45 46	17.	Flodin L, Sääf M, Cederholm T, Al-Ani AN, Ackermann PW, Samnegård E, Dalen N, Hedström M.
47		Additive effects of nutritional supplementation, together with bisphosphonates, on bone mineral density
48 49		after hip fracture: a 12-month randomized controlled study. Clinical interventions in aging. 2014;9:1043.
50 51		
52	18.	Bauer, J.M., Verlaan, S., Bautmans, I., Brandt, K., Donini, L.M., Maggio, M., McMurdo, M.E., Mets, T.,
53 54		Seal, C., Wijers, S.L. and Ceda, G.P. Effects of a vitamin D and leucine-enriched whey protein nutritional
55		supplement on measures of sarcopenia in older adults, the PROVIDE study: a randomized, double-blind,
		placebo-controlled trial. Journal of the American Medical Directors Association 2015:16(9), pp.740-747.

19. Delomas C, Hertzog M, Vogel T, Lang PO. Vitamin D supplementation in nursing home residents: Randomized single cholecalciferol loading protocol vs. individualized loading dose regimen. The journal of nutrition, health & aging. 2017 Apr 1;21(4):421-8. 20. Lagari V, Gómez-Marín O, Levis S. The role of vitamin D in improving physical performance in the elderly. Journal of Bone and Mineral Research. 2013 Oct;28(10):2194-201. 21. Ribaldone, D.G., Astegiano, M., Actis, G.C. and Pellicano, R., 2020. Management of inflammatory bowel disease during COVID-19 pandemic. MINERVA GASTROENTEROLOGICA E DIETOLOGICA 2020: 66, 106-112 22. Bischoff-Ferrari HA, Dawson-Hughes B, Orav EJ, Staehelin HB, Meyer OW, Theiler R, Dick W, Willett WC, Egli A. Monthly high-dose vitamin D treatment for the prevention of functional decline: a randomized clinical trial. JAMA internal medicine. 2016:1;176(2):175-83. 26 23. Wood AD, Secombes KR, Thies F, Aucout LS, Black AJ, Reid DM, Mavroeidi A, Simpson WG, Fraser WD, Macdonald HM. A parallel group double-blind RCT of vitamin D 3 assessing physical function: is the biochemical response to treatment affected by overweight and obesity?. Osteoporosis International. 2014:25(1):305-15. 24. Jolliffe DA, Camargo Jr CA, Sluyter JD, Aglipay M, Aloia JF, Ganmaa D, Bergman P, Bischoff-Ferrari HA, Borzutzky A, Damsgaard CT, Dubnov-Raz G. Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials. The Langet Diabetes & Endocrinology 2021:30. 25. Witham MD, Price RJ, Struthers AD, Donnan PT, Messow CM, Ford I, McMurdo ME. Cholecalciferol treatment to reduce blood pressure in older patients with isolated systolic hypertension: the VitDISH randomized controlled trial. JAMA internal medicine 2013:14;173(18):1672-9. ⁵⁰ 26. Vitezova A, Muka T, Zillikens MC, Voortman T, Uitterlinden AG, Hofman A, Rivadeneira F, Kiefte-de Jong JC, Franco OH. Vitamin D and body composition in the elderly. Clinical Nutrition 2017: 1;36(2):585-92.

Page 9 of 24

27. Perna S. Is Vitamin D supplementation useful for weight loss programs? A systematic review and metaanalysis of randomized controlled trials. Medicina. 2019:55(7):368.

1	analysis of randomized controlled trials. Medicina. 2019:55(7):368.
3	
4	
5	
7	
2 3 4 5 6 7 8 9	
9	
10 11	
12	
13	
14	
15 16	
17	
18	
19 20	
21	
22 23	
23 24	
25	
26	
27 28	
28	
30 31	
31	
32 33	
34	
34 35 36	
36 37	
38	
39	
40 41	
38 39 40 41 42 43	ATTRANCE GION
43	
44 45	
46	
44 45 46 47 48	
48 10	
49 50	
51	
52 52	
54	
55	
49 50 51 52 53 54 55	

Page 10 of 24

Table 1. Effect of vitamin D supplementation in elderly with obesity and overweight (Main studies from 2010

to 2020) 1 2 3

Author (year	Participants	Design of	Mean	Mean	Dosage	Treatment	Serum Vit D
ðf		the study	age	BMI		duration	DELTA + ds
8 pubblication) 10						\square	
1 S ollid, 2014	511	Randomized	65.1	29.9	20.000 UI per	1 year	Treat: 45.8
12		double blind	years	kg/m2	week or	$\langle \bigcirc \rangle \checkmark$	+/-24.2
13 14		placebo-	-	-	placebo		nmol/l
15		-			placebo		
16 17		controlled					Placebo: 3.4
18		trial				510 ⁵⁵	+/-16.9
19				/		4. (3)))	nmol/l
20 2 T omi-Pekka,	73	Randomized	65.7	29.4	40 mcg	5 months	PLACEBO:
22 23015	15				$\langle \rangle$	/ 5 months	
		placebo	years	kg/m2	80 mcg		4.1 +/-17.3
24 25		double	$\langle \rangle$	\sim	A GC		nmol/l.
26		blinded trial	$\langle \rangle \rangle$	\sim			TREAT 40:
27			$\langle \rangle$				
28			$\langle \rangle$		2		+27.7 +/-
29 30			Ň,				17.2 nmol/l.
31							TREAT 80:
32		\bigcirc		-			
33		\searrow					+45.0 +/-
34 35							23.4 nmol/l.
36 ₃ Vlacdonald,	305	Double blind	60-70	>25.0	400 UI	1 year	400 UI:
	303					i year	
³² 013 39	(\bigcirc) \lor	placebo	ys	kg/m2	1000 UI daily		+31.6 +/-
40		controlled					19.8 nmol/l
41 42		trial					1000 UI:
42							
44	\sim						+42.6 +/-
45							18.9 nmol/l
46							PLACEBO: -
47 48							
49							4.1 +/-11.5
50							
51 5017	120	Doudousiand	72.4	20.7		0 m o m th a	
52evis, 2017 53	130	Randomized	72.4	30.7	4000 UI daily	9 months	TREAT: +
54		double	years	kg/m2			23.0 +/-14.2
55							ng/ml.

Page 11 of 24

		blinded					PLACEBO:
		placebo trial					1.2 +/-5.8
1 2		-					ng/ml.
3							<u>g</u> ,
4							
Vijnen, 2015	30	Randomized	> 65	31	LD: 2 gruppi,	6 months	LD: 61
7			years	kg/m2	entrambi treat.		nmol/l (54-
8 9					Loading dose	\bigwedge	72).
10 11					50.000 UI		DD: 44
12 13						$\langle \rangle \rangle$	nmol/l (26-
13 14							50).
15							
1 D elomas,	111	Randomized	85.1	25.0	4 x 100.000 UI	2 months	TREAT:
17 18 ⁰¹⁷		single	years	kg/m2	vs		50.2 +/- 15.4
19 20		blinded		<	individualized	¢ O	ng/ml
21		controlled			load (400.000	\mathbb{P}^{\sim}	PLACEBO:
22 23		study		$\langle \rangle \rangle$	o 300.000 o		35.8 +/- 6.5
24			\sim	$\langle \langle \cdot \rangle$	200,000)		ng/ml
25 26			\sim	\searrow	200,000)		iig/iiii
27							
218 agari, 2013	86	Randomized	73,4	25.9	400 o 2000 UI	6 months	+ 2.4 +/-12.0
29 30		trial	years	kg/m2	daily		ng/ml
31			_	\rightarrow			M 400: -1.2
32 33	<		(O)				+/-5.9
34							M 2000: 6.1
35 36							
37							+/-12.6
38 39	$\bigcirc \lor \checkmark$	and los					F 400: -3.4
40	\times ,	In the second se					+/-10.8
41 42		\rightarrow					F 2000: 5.3
43	Mr.						+/-12.3
44 4∮irotta, 2015	26	Double	> 65		2000 111	10 weeks	TREAT: +34
46	20				2000 UI	TU WEEKS	
47 48		blinded	years				+/- nmol/l
49		placebo					PLACEBO: -
50 51		controlled					$1.2 \pm - nmol/l$
52 53		randomized					
53 54		trial					
54 55							

Page 12 of 24

Flodin, 2014	79	Randomized	79	28	800 UI/d	1	12 months	Placebo:	17
1		trial	years	kg/m2				+/-22 nm	nol/l
1 2								G1: 18 +	+/-37
3 4								nmol/l	
5								G2: 20 +	+/-24
5 6 7								nmol/l	
8 Bauer, 2015	380	Multicenter	77.7	26.1	Twice	daily	13 weeks	TREAT:	
10 11		randomized	years	kg/m2	800 UI	5		+25.0 (1	
12		double blind	5	6			$\langle \rangle \rangle$	39.0) nm	
13 14		trial				C	s à	PLACEE	
15 16						((\sim	11.0-
17						\sim		0.0) nmo	
18 19						\bigcirc		0.0) 11110	1/1
20 21				\sim					
22				\square	\rightarrow	્રે			
23 24			\wedge	$\backslash \backslash /$		0>			
25 26			\sim			/			
27			$\sim \sim$						
28 29					9				
30 31			\sim						
32	/	$ \rightarrow $		\succ					
33 34	\wedge	ST 10- Cor							
35 36			2						
37									
38 39		allos							
40		I A A A A A A A A A A A A A A A A A A A							
41 42		>							
43 44	Per								
45									
46 47									
48									
49 50									
51 52									
53									
.54									
54 55									

Page 13 of 24

The Enigma of Vitamin D supplementation in Aging with Obesity

Simone PERNA¹

¹Department of Biology, College of Science, University of Bahrain, P.O. Box 32038, Sakhir, Bahrain.

Corresponding author: Simone Perna, Section, Department of Biology, College of Science, University of Bahrain, P.O. Box 32038, Sakhir, Bahrain. Mail correspondence simoneperna@hotmail.it

Abstract

INTRODUCTION: The American Geriatrics Society recommends a minimum daily supplement of 1,000 IU and underlines that a dosage lower than 600 IU do not prevent falls in elderly people.

EVIDENCE ACQUISITION: Review author searched on PubMed, Medline, Embase, Scopus database (last search May 30, 2021), with the MeSH terms and keywords of vitamin (2, (25(OH)D), elderly and obesity. This review article aims to support the rationale on the correct vitamin D supplementation in elderly people with obesity and overweight.

EVIDENCE SYNTHESIS: 10 studies were found suitable for consideration in writing this comprehensive evidence-based rapid review. The supplementation of vitamin D included 1500 elderly subjects with Body Mass Index (BMI) over 25 kg/m². This article shows that the daily vitamin D supplementation from 2000 to 4000 UI is highly recommended in elderly people with obesity because 1) sequestration of vitamin D by the adipose tissue 2) increased catabolism of vita-in D in the adipose tissue 3) decreased synthesis of serum 25 hydroxyvitamin D (25(OH)D) in the liver 4) reduced sun-exposure. 5) Dosages equal at 1000 UI or lower do not show and important effect on vitamin d deficiency and related comorbidities in elderly people with obesity. CONCLUSIONS: Gender, baseline levels of serum (25(OH)D) concentration, ethnicity and severity of BMI should be accounted for the correct supplementation of vitamin D in elderly population for the precision medicine goal.

Key words: vitamin D; elderly; sarcopenia, serum 25 hydroxyvitamin D

INTRODUCTION.

The vitamin D system includes a group of fatty-soluble prohormones and their corresponding metabolites. [1]. There are two main forms of vitamin D in nature: vitamin D2 (ergocalciferol), photochemically synthesized in plants, and vitamin D3 (cholecalciferol), synthesized by the skin in response to exposure to sunlight. The levels of vitamin D derive mainly from the endogenous skin production stimulated by sunlight and by oral intake [2-3]. In elderly people have been demonstrated that there is an inverse association between serum 25 (OH) D concentration and a Body Mass Index (BMI) greater than 25 kg/ m2 [4].

It is unclear whether this association is due to increased fat deposition, a sedentary lifestyle, low sun exposure, direct vitamin D deficiency, genetic changes in vitamin D metabolism, or other unknown factors [5].

The presence of a vitamin D deficiency in obese people shows a negative relationship between (25(OH)D) and body fat percentage. This marked unbalanced ration is higher for some ethnicities, and the relationship is more evident in older people rather than young [6]. Furthermore, some studies have shown that the reduction on body weight and percentage of fat mass are associated with an increase in circulating levels of (25(OH)D) [7,8]. There are several reasons behind of this situation: 1) the volumetric dilution, in particular, the serum levels of vitamin D are reduced as well as body mass and therefore the amount stored in fat increases, 2) different lifestyles between obese and underweight people 3) different ability to activate vitamin D between obese and underweight people due to the levels of the enzymes activating vitamin D, 25-hydroxylase CYP2J2 and 1a-hydroxylase CYP27B1, 4) the sequestration of vitamin D into the adipose tissue [9].

The aim of this review is to shed in light and define the dose-efficacy of the vitamin D supplementation in
 elderly patients with overweight and obesity.

5 EVIDENCE ACQUISITION

This systematic review was performed according to the following steps suggested by Egger [10]: (i) configuration of a working group; (ii) formulation of the revision question on the basis of considerations made in the abstract; (iii) identification of relevant studies. The search involved all the studies published from the 1st of January 2010 the 30th May 2021. English written articles were identified by searching on PubMed, Medline, Embase, Scopus database (last search May 30, 2021), with the MeSH terms and keywords of vitamin D, (25(OH)D), elderly and obesity.

46 (SP) independently reviewed each report. For each of the relevant abstracts, full publications were retrieved
47 for evaluation on the basis of criteria established a priori.

Original clinical trials investigating the effects of vitamin D supplementations (divided for dose intervention)
in elderly patients were evaluated. The change of vitamin D level (t1 minus t0 basal level) was the primary
outcome considered. Only elderly patients with age over 65 years old were included with overweight and
obesity. The eligible studies were required to report baseline and follow-up values, i.e. the mean change from

baseline (Δ -change) and/or the mean difference Δ -changes (MD Δ) between intervention groups for Vitamin D outcome.

EVIDENCE SYNTHESIS

1

2

Table 1 shows 10 studies with more than 1500 elderly subjects with overweight and obesity. All studies
showed a clinical effect of vitamin D supplementation compared to placebo, but significant effects "between
groups" were reported in studies with daily supplementation from 2000 to 4000 UI. Sollid, 2014 et al (11)
reported an increase of 45.8 nmol/L in intervention group with vitamin D 20.000 UI/weekly compared with
placebo 3.4 nmol/L, respectively, nevertheless a situation of obesity.

Similar effects were reported in the study of Tomi-Pekka with a supplementation of 80 μ g/d vitamin D3 daily (12), but not in the study of Macdonald with a lower supplementation (1000 UI daily). (13),

In 2017, Levis at al, showed that daily cholecalciferol 4,000 IU for 9 months increased the (25(OH)D) concentrations, nevertheless the population was with obesity (14).

There was not recorded any improvement in (25(OH)D) on recent clinical trials with low dosages (15-17). Very interesting data were reported by 3 recent studies (18-20) that reported an high efficacy of vitamin D supplementation ((25(OH)D) increased +50% from baseline) in obese patients at dosages of vitamin D (from 2000 to 300.000 IU).

30 CONCLUSIONS

28 29

This review shows that in elderly patients with a BAT over 25 kg / m2 (both in overweight and obese) a daily vitamin D supplementation from 2000 IU and above could be a real effective treatment for raising the levels of (25(OH)D) instead the normal recommended dosage of 1000-800 IU daily.

In this category of patients, the areas of effectiveness of vitamin D intake are multiples such as the quality of life, the prevention of sarcopenia, the reduction of depression, the reduction in the incidence of fractures, pain reduction, the reduction in the incidence of infections and the improvement of physical function (21-23)

Considering the positive effects of vitamin D in elderly on the following areas, the identified dosage must be
standardized whenever possible, at 2000 IU / day and above when it is possible.

No effects of vitamin D supplementation was found in situations of sarcopenia (at the dose of 800 IU [16]),
to improve physical functions at the dose of 400 IU [22]), cytokine suppression at the dose of 750 IU [23]),
blood pressure and glucose homeostasis (from 250 to 400 IU [24-26]).

Furthermore the patients with obesity (BMI over 30Kg / m2) have found positive effects (at doses ranging
from 2000 to 4000 IU daily) in improving physical functions, in association between protein intake and bone
mineral density, and increased concentration of serum 25 (OH) D levels, the latter factor is of great scientific

interest and of current importance, as it can determine (through the presence of fat mass) a sequestration of the supplemented vitamin D. (27)

It is known that the concentrations of serum (25(OH)D) are less in obese individuals and in particular in elderly. There are several mechanisms described in the literature that shows the involvement of vitamin D in adipose tissue metabolism and catabolism in elderly. Summarizing this founding, the vitamin D supplementation over 2000 UI is highly recommended in elderly obese because 1) sequestration of vitamin D by the adipose tissue 2) increased catabolism of vitamin D in the adipose tissue 3) decreased synthesis of 25(OH)D in the liver 4) reduced sun-exposure.

This study lays the foundation for identifying the effectiveness of proper vitamin D supplementation in elderly patients with obesity. The importance of supplementation must be assessed by taking into consideration various determining factors such as: the basal serum dose, gender, age and the BMI

Author Contributions: SP is full responsible for "Conceptualization; methodology; resources; writing-orig-

inal draft preparation, andreview and editing,

Funding: "This research received no external funding"

Conflicts of Interest: The authors declare no conflict of interest."

REFERENCES

- Liu H, Li J, Du L, Yang M, Yang D, Li J, et al. Short-term effects of core stability training on the balance and ambulation function of individuals with chronic spinal cord injury: a pilot randomized controlled trial. Minerva Med 2019;110:216-23.
- 2. Sirajudeen S, Shah, I, Al Menhali, A. A narrative role of vitamin D and its receptor: with current evidence on the gastric tissues. International journal of molecular sciences 2019 20(15), 3832,
- 3. Giuliani S, Barbieri V, Di Pierro A, M Rossi F, Widmann T, Lucchiari M, Herrmann M DC–MS/MS based 25 (OH) D status in a large Southern European outpatient cohort: gender-and age-specific differences. European journal of nutrition 2019 58(6), 2511-2520.
- Curic N, Ilincic B, Milic N, Cabarkapa V, Nikolic S, Medic-Stojanoska M, Pellicano R, Abenavoli L. The relationship between the vitamin serum 25 (OH) D and the B12 concentrations in obese women. Minerva medica. 2017: 7;109(2):79-87.
- 5. Charoenngam N, Shirvani A, Holick MF. Vitamin D for skeletal and non-skeletal health: What we should know. Journal of clinical orthogaedics and trauma 2019:10(6), 1082-1093.
 - Gallagher JC, Peacock M, Yalamanchili V, Smith LM. Effects of vitamin D supplementation in older African American women. The Journal of Clinical Endocrinology & Metabolism 2013:1;98(3):1137-46.
- Parva NR, Tadepalli S, Singh P, Qian A, Joshi R, Kandala H, Nookala VK, Cheriyath P. Prevalence of vitamin D deficiency and associated risk factors in the US population (2011-2012). Cureus 2018:10(6).
- Vilarrasa N, Maravall J, Estepa A, Sanchez R, Masdevall C, Navarro MA, Alía P, Soler J, Gómez JM. Low 25-hydroxyvitamin D concentrations in obese women: their clinical significance and relationship with anthropometric and body composition variables. Journal of endocrinological investigation. 2007:30(8):653-8.
- Mazahery H, Von Hurst PR. Factors affecting 25-hydroxyvitamin D concentration in response to vitamin D supplementation. Nutrients 2015:7(7):5111-42.

10. Abbas MA. Physiological functions of Vitamin D in adipose tissue. The Journal of steroid biochemistry and molecular biology 2017:165, 369-381.

- 11. Egger, M., Davey-Smith, G. and Altman, D. eds., 2008. Systematic reviews in health care: meta-analysis in context. John Wiley & Sons.
- 12. Sollid ST, Hutchinson MY, Fuskevåg OM, Figenschau Y, Joakimsen RM, Schirmer H, Njølstad I, Svartberg J, Kamycheva E, Jorde R. No effect of high-dose vitamin D supplementation on glycemic status or cardiovascular risk factors in subjects with prediabetes. Diabetes care 2014:1:37(8):2123-31.
- Tuomainen TP, Virtanen JK, Voutilainen S, Nurmi T, Mursu J, de Mello VD, Schwab U, Hakumäki M, Pulkki K, Uusitupa M. Glucose metabolism effects of vitamin D in prediabetes: the VitDmet randomized placebo-controlled supplementation study. Journal of diabetes research. 2015:27;2015.
- 14. Macdonald HM, Wood AD, Aucott LS, Black AJ, Fraser WD, Mavroeidi A, Reid DM, Secombes KR, Simpson WG, Thies F. Hip bone loss is attenuated with 1000 IU but not 400 IU daily vitamin D3: a 1-year double-blind RCT in postmenopausal women. Journal of Bone and Mineral Research. 2013:28(10):2202-13.
- 15. Levis, S., & Gómez-Marín, O (2017). Vitamin D and physical function in sedentary older men. Journal of the American Geriatrics Society, 65(2), 323-331.
- 16. Wijnen H, Salemink D, Roovers L, Taekema D, de Boer H. Vitamin D supplementation in nursing home patients: randomized controlled trial of standard daily dose versus individualized loading dose regimen. Drugs & aging. 2015:1;32(5):371-8.
- 17. Flodin L, Sääf M, Cederholm T, Al-Ani AN, Ackermann PW, Samnegård E, Dalen N, Hedström M. Additive effects of nutritional supplementation, together with bisphosphonates, on bone mineral density after hip fracture: a 12-month randomized controlled study. Clinical interventions in aging. 2014;9:1043.

- 18. Bauer, J.M., Verlaan, S., Bautmans, I., Brandt, K., Donini, L.M., Maggio, M., McMurdo, M.E., Mets, T., Seal, C., Wijers, S.L. and Ceda, G.P. Effects of a vitamin D and leucine-enriched whey protein nutritional supplement on measures of sarcopenia in older adults, the PROVIDE study: a randomized, double-blind, placebo-controlled trial. Journal of the American Medical Directors Association 2015:16(9), pp.740-747.
- 19. Delomas C, Hertzog M, Vogel T, Lang PO. Vitamin D supplementation in nursing home residents: Randomized single cholecalciferol loading protocol vs. individualized loading dose regimen. The journal of nutrition, health & aging. 2017 Apr 1;21(4):421-8.
- 20. Lagari V, Gómez-Marín O, Levis S. The role of vitamin D in improving physical performance in the elderly. Journal of Bone and Mineral Research. 2013 Oct;28(10):2194-201
- 21. Ribaldone, D.G., Astegiano, M., Actis, G.C. and Pellicano, R., 2020. Management of inflammatory bowel disease during COVID-19 pandemic. MINERVA GASTROENTEROLOGICA E DIETOLOG-ICA 2020: 66, 106-112
- 22. Bischoff-Ferrari HA, Dawson-Hughes B, Orav EJ, Staehelin HB, Meyer OW, Theiler R, Dick W, Willett WC, Egli A. Monthly high-dose vitamin D treatment for the prevention of functional decline: a randomized clinical trial. JAMA internal medicine. 2016:1;176(2):175-83.
- 23. Wood AD, Secombes KR, Thies F, Aucott LS, Black AJ, Reid DM, Mavroeidi A, Simpson WG, Fraser WD, Macdonald HM. A parallel group double-blind RCT of vitamin D 3 assessing physical function: is the biochemical response to treatment affected by overweight and obesity?. Osteoporosis International 2014:25(1):305-15.
- 24. Jolliffe DA, Camargo Jr CA, Sluyter JD, Aglipay M, Aloia JF, Ganmaa D, Bergman P, Bischoff-Ferrari HA, Borzutzky A, Damsgaard CT, Dubnov-Raz G. Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials. The Lancet Diabetes & Endocrinology 2021:30.
- 25. Witham MD, Price RJ, Struthers AD, Donnan PT, Messow CM, Ford I, McMurdo ME. Cholecalciferol treatment to reduce blood pressure in older patients with isolated systolic hypertension: the VitDISH randomized controlled trial. JAMA internal medicine 2013:14;173(18):1672-9.

- 26. Vitezova A, Muka T, Zillikens MC, Voortman T, Uitterlinden AG, Hofman A, Rivadeneira F, Kieftede Jong JC, Franco OH. Vitamin D and body composition in the elderly. Clinical Nutrition 2017: 1;36(2):585-92.
- 27. Perna S. Is Vitamin D supplementation useful for weight loss programs? A systematic review and meta-analysis of randomized controlled trials. Medicina. 2019:55(7):368.

THERE CE

3500000 Caller

Ø

Table 1. Effect of vitamin D supplementation in elderly with obesity and overweight (Main studies from 2010 to 2020)

Author (year	Participants	Design of	Mean	Mean	Dosage	Treatment	Serum	Vit
of		the study	age	BMI		duration	D DEL	ΤA
pubblication)						$\langle \rangle$	¥ ds	
Sollid, 2014	511	Randomized	65.1	29.9	20.000 UI per	-1 year	Treat:	15.8
		double blind	years	kg/m2	week or		€/→24.2	
		placebo-			placebo	10 mg	nmol/l	
		controlled		<			Placebo:	3.4
		trial				\geqslant	+/-16.9	
				$\langle \langle \rangle \rangle$			nmol/l	
Tomi-Pekka,	73	Randomized	65.7	29,4	40 mcg	5 months	PLACE	30:
2015		placebo	years	kg/m2	80 mcg		4.1 +/-1	7.3
		double			<i>Y</i>		nmol/l.	
		blinded trial					TREAT	40:
							+27.7	+/-
							17.2 nmo	ol/l.
							TREAT	80:
		J. 602					+45.0	+/-
		\geq					23.4 nmo	ol/l.
Macdonald,	305	Double	60-70	>25.0	400 UI	1 year	400	UI:
2013	\sim	blind	ys	kg/m2	1000 UI daily		+31.6	+/-
		placebo					19.8 nmo	ol/l
		controlled					1000	UI:
		trial					+42.6	+/-
							18.9 nmo	ol/l

1

2 3 4

1 2 3								PLACEBO: -4.1 +/-11.5
4 5								-4.1 +/-11.5
3 4 5 6 7 8	Levis, 2017	130	Randomized	72.4	30.7	4000 UI daily	9 months	TREAT: +
9 10			double	years	kg/m2		\sim	23.0 +/-14.2
11 12			blinded					ng/ml.
13			placebo trial					PLACEBO:
14 15							$\left(\right) \right) \right\rangle$	1.2 +/-5.8
16 17								ng/ml.
18 19								
20 21	Wijnen, 2015	30	Randomized	> 65	31	LD: 2 gruppi,	6 months	LD: 61
22 23				years	kg/m2	entrambi		nmol/l (54-
24 25					$\bigvee \qquad \qquad$	treat. Loading		72).
26 27				$\langle \rangle$		dose 50.000		DD: 44
28 29				\square		Ŭ		nmol/l (26-
30 31								50).
32 33	Delomas,	111	Randomized	85.1	25.0	4 x 100.000	2 months	TREAT:
34 35	2017		single	years	kg/m2	UI vs		50.2 +/-
36 37			blinded			individualized		15.4 ng/ml
38 39			controlled			load (400.000		PLACEBO:
40 41			study			o 300.000 o		35.8 +/- 6.5
42						200.000)		ng/ml
43 44								
45 46	Lagari, 2013	86	Randomized	73.4	25.9	400 o 2000 UI	6 months	+ 2.4 +/-
47 48			trial	years	kg/m2	daily		12.0 ng/ml
49 50								M 400: -1.2
51 52								+/-5.9
53 54								M 2000: 6.1
55								+/-12.6

F					1		1	
								F 400: -3.4
								+/-10.8
								F 2000: 5.3
								+/-12.3
	Pirotta, 2015	26	Double	> 65		2000 UI	10 weeks	TREAT:
			blinded	years				+34 +/-
			placebo					nmol
			controlled				\longrightarrow	PLACEBO:
			randomized					-1.2 +/-
			trial					nmol/l
_			ulai				<u>~</u> (3)~	111101/1
	Flodin, 2014	79	Randomized	79	28	809 UI/d	12 months	Placebo:
			trial	years	kg/m2			17 +/-22
					$\sum $			nmol/l
				$\bigcirc \bigcirc \bigcirc$	$\langle \rangle \langle \rangle$			G1: 18 +/-
				$2 \wedge $	SUC SUC			37 nmol/l
				\bigvee				G2: 20 +/-
				Ì	>			24 nmol/l
_	Bauer, 2015	380	Multicenter	77.7	26.1	Twice daily	13 weeks	TREAT:
	Dauci, 2013			-//./	20.1	I will daily	15 weeks	INL/YI.
			randomized	years	kg/m2	800 UI		+25.0 (14.0-
			double blind					39.0) nmol/l
			trial					PLACEBO:
								-6.0 (-11.0-
		Man						0.0) nmol/l
L				l	I		1	

Supplementary Digital Material

Download supplementary material file: Minerva Gastroenterol-2955_Supplementary Digital Material1_V2_2021-06-19.docx HURNA COSTOR THE CONTRACT OF THE CONTRACT OF THE COSTOR OF

- 2 3 4